Few research peptides have a reputation as large as BPC-157. Search for it online and you will find confident claims about tendons, joints, guts, and brains, often presented as settled fact. Search for it on PubMed and you will find something different: a long, genuinely interesting body of animal work, a much thinner layer of independent replication, and almost no controlled human data.
This article walks through what the published record actually contains, who produced it, and where the honest boundaries of the evidence sit today.
What BPC-157 is
BPC-157 is a synthetic pentadecapeptide, meaning a chain of 15 amino acids. Its name stands for "body protection compound," and it was described as a partial sequence of a larger protein that researchers reported finding in human gastric juice. The sequence studied in the literature is GEPPPGKPADDAGLV (Staresinic 2003).
Two features made it attractive to researchers. First, it is reported to be unusually stable in gastric juice for a peptide, which is why so many animal studies gave it by mouth or in drinking water as well as by injection. Second, early gastrointestinal work suggested broad protective effects on the stomach and gut lining, which led the originating group to test it in one tissue model after another.
Where the research comes from
The single most important fact about the BPC-157 literature is its origin. The large majority of published papers come from one research group in the Department of Pharmacology at the University of Zagreb in Croatia, led for decades by Predrag Sikiric, with Sven Seiwerth and many collaborators. Their output is enormous and spans ulcers, intestinal anastomoses, tendon and ligament injury, muscle crush models, bone defects, blood vessel occlusion, and drug toxicity models.
That concentration matters for a simple reason. In science, a finding becomes robust when unrelated labs, using their own methods and materials, reproduce it. When most of a literature flows from one group, the whole record shares that group's methods, animal strains, outcome measures, and interpretive framework. None of this means the work is wrong. It means it has not been stress-tested the way a field with many independent teams would be.
The Zagreb group's own reviews make broad claims. One argues that BPC-157 was consistently effective across acute and chronic injury models from the esophagus through the lower gut, and that it improved tendon, ligament, and bone healing using the same regimens as in gastrointestinal studies (Seiwerth 2018). Readers should treat those conclusions as the view of the originating lab summarizing its own program.
The tendon and musculoskeletal studies
The musculoskeletal claims that dominate internet discussion trace back largely to rodent injury models.
A representative example is the rat Achilles tendon transection study (Staresinic 2003). Researchers cut the Achilles tendon in rats and compared animals given BPC-157 with saline controls. Treated rats showed better functional scores, higher load to failure, more organized collagen under the microscope, and smaller tendon defects over two weeks. The same paper reported that BPC-157 countered the growth-inhibiting effect of an oxidative aldehyde on cultured tendon cells.
Independent support does exist, though it is modest. A group at Chang Gung University in Taiwan studied tendon fibroblasts taken from rat Achilles tendons (Chang 2011). BPC-157 did not directly increase cell proliferation, but it increased outgrowth of cells from tendon explants, improved cell survival under oxidative stress, and increased cell migration, which the authors linked to activation of the FAK and paxillin signaling pathway. This is cell culture work, not an injury study, but it is one of the more cited examples of a lab outside Zagreb reporting a mechanism.
A 2025 systematic review from an orthopedic sports medicine perspective put the whole record in numbers (Vasireddi 2025). After screening 544 articles published from 1993 to 2024, the authors included 36 studies. Thirty-five were preclinical. One was clinical. They described the evidence base as level IV and level V studies, the lowest tiers of the evidence hierarchy, and concluded that the peptide "shows promise" while cautioning about unknown clinical safety and unregulated manufacturing.
Mechanism: what the animal work proposes
Across the preclinical literature, several mechanisms are proposed. Reviews describe effects on angiogenesis through VEGF receptor 2 signaling, on nitric oxide production through the Akt and eNOS pathway, on ERK1/2 signaling, on growth hormone receptor expression, and on inflammatory cytokines (McGuire 2025; Vasireddi 2025).
It is worth being clear about what that list represents. These are pathways observed in rodent tissue and cultured cells, sometimes in a single study. A long list of mechanisms can look like strength, but it can also signal that no single, well-defined target has been established. There is no identified receptor for BPC-157 comparable to the well-characterized receptors behind approved peptide drugs such as the ones discussed in our explainer on GLP-1 receptor agonists.
Pharmacokinetics and preclinical safety
One of the more useful recent additions to the literature came from a group at the Air Force Medical University in Xi'an, China, which was developing BPC-157 as a potential wound-healing drug. Their pharmacokinetic study in rats and beagle dogs found that the intact peptide had an elimination half-life of under 30 minutes after injection, and that it was rapidly broken down into smaller peptide fragments and then single amino acids, cleared mainly through urine and bile (He 2022). Bioavailability after intramuscular injection differed markedly between species.
The same group reports having completed formal preclinical safety studies before that work, and the systematic review described below likewise found no adverse effects in preclinical safety studies across several organ systems (Vasireddi 2025). These data are valuable precisely because they come from a lab outside Zagreb working toward a regulatory filing. They are still animal data, and animal safety studies do not establish human safety.
What human data exist
This is where the gap between online claims and the published record is widest. As of the most recent reviews, only three small human reports have been published, all sharing the same lead author, all from private clinical practice, and all in the same journal (McGuire 2025).
- Knee pain chart review. A retrospective review of 16 patients who had received intra-articular BPC-157, some combined with thymosin beta-4, found that most reported pain relief when contacted by phone months later (Lee 2021). There was no control group, no blinding, no standardized outcome measures, and follow-up varied between patients.
- Interstitial cystitis pilot. Twelve women with interstitial cystitis who had not responded to standard therapy received BPC-157 injections into the bladder wall during cystoscopy, and all reported improvement on a global response questionnaire (Lee 2024). Again, there was no placebo arm, and the outcome was self-reported.
- Intravenous safety pilot. A 2025 report from the same lead author described two adults who received intravenous BPC-157 on consecutive days with no changes in the blood markers measured. Two participants, both of whom had used the peptide before, cannot establish safety for anyone.
Earlier, a pharmaceutical company developed the molecule under the code names PL 14736 and PLD-116 for inflammatory bowel disease, and it was described in 2003 as being in clinical trials (Staresinic 2003). Full peer-reviewed results from that program were never published in a way that settles any clinical question.
The plain summary: there is no randomized, placebo-controlled trial of BPC-157 for any musculoskeletal or gastrointestinal outcome in people. The systematic review authors found no clinical safety data at all within their search window (Vasireddi 2025).
Regulatory and sport status
BPC-157 is not approved by the US Food and Drug Administration for any use. The FDA previously listed BPC-157 in Category 2 of its interim policies on bulk drug substances nominated for use in compounding, the category for substances the agency considers to present potential significant safety risks. That nomination was later withdrawn: the FDA's page (content current as of April 2026) now lists BPC-157 among substances "nominated but withdrawn" that were previously in Category 2, and it still carries the agency's summary of safety concerns. A withdrawn nomination is not an approval. The agency's stated concerns centered on limited human safety data and the potential for immunogenicity, including from peptide-related impurities. Regulatory positions can change, so anyone tracking this should check the FDA's current list directly.
In sport, the World Anti-Doping Agency lists BPC-157 by name as an example under section S0, non-approved substances, which are prohibited at all times. Clinical reviewers have repeatedly flagged this for athletes (Vasireddi 2025).
Reading the claims critically
When you see a confident statement about BPC-157 online, a few questions help sort signal from noise:
- Which species? Almost every positive outcome comes from rats or mice, often with surgically created injuries that heal differently from chronic human conditions.
- Which lab? Check whether the study came from the originating Zagreb group or an independent team.
- Was there a control? The human reports to date have no placebo arm, which matters enormously for pain and symptom scores.
- What was actually in the vial? Unregulated products vary in identity and purity, and a study, or a claim, is only as good as the material behind it. Our guides on reading a certificate of analysis and what makes a peptide research grade explain how to evaluate that.
BPC-157 has a large and interesting animal literature, a small independent literature, and almost no controlled human evidence.
That is not a dismissal. Plenty of useful drugs began as a single lab's persistent rodent work. But the step from promising animal data to demonstrated human benefit is exactly the step BPC-157 has not yet taken, and reviewers across orthopedics and sports medicine agree it should be treated as investigational until well-designed trials are done (McGuire 2025).
For a related family of compounds with a much deeper human trial record, including one FDA-approved drug, see our field guide to growth hormone secretagogues.
Correction, Sept 27, 2026: an earlier version said the FDA placed BPC-157 in Category 2 of its compounding list in 2023 without noting that the nomination was later withdrawn. The regulatory section now reflects the FDA's current page.
Sources and further reading
- Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. doi.org/10.1016/S0736-0266(03)00110-4
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. doi.org/10.1152/japplphysiol.00945.2010
- Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and standard angiogenic growth factors. Gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing. Curr Pharm Des. 2018;24(18):1972-1989. doi.org/10.2174/1381612824666180712110447
- He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. doi.org/10.3389/fphar.2022.1026182
- Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27(4):8-13. pubmed.ncbi.nlm.nih.gov/34324435/
- Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024;30(10):12-17. pubmed.ncbi.nlm.nih.gov/39325560/
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21(4):485-495. doi.org/10.1177/15563316251355551
- McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. doi.org/10.1007/s12178-025-09990-7
Peptrend.Health is an educational publication. Content on this site is for informational and research purposes only and is not medical advice, and it is not a substitute for guidance from a qualified professional. Products referenced from Prime Core Dynamics are sold for laboratory research use only and are not intended for human consumption.